张金,博士,助理研究员。2022年加入中国科学院深圳先进技术研究院,主要研究方向为新型生物医用功能材料构建及疾病诊疗相关研究。包括开发疾病特异性靶向递送技术、研制多种激活型成像探针,涉及pH、MMP-2酶及Caspase-3酶响应型超声、光声、核磁成像等影像学及治疗应用。在Biomaterials, ACS Nano, Advanced Functional Materials, Chemical Engineering Journal等学术期刊上发表SCI论文10余篇,其中第一作发表7篇,总影响因子大于80,在关键体内医用材料设计制备、靶向改造加工上具有良好研究工作基础。参与多项科技部国家重点研发计划项目以及国家自然科学基金委项目。

  1.Jin Zhang; Quan Xu; Yifang Zhang; Mohamed F. Foda; Kai Cai; Qing Liu; Fan Jia; Huadong Wang; Fuqiang Xu*; Heyou Han*; Huageng Liang*; Natural bioactive lysosomes extracted from multiple cells for tumor therapy, Biomaterials, 2024, 304: 122430.

  2.Jin Zhang#; Yongli Mu#; Mengqin Xu; Mohamed F. Foda; Heyou Han*; Sequential assembled chimeric peptide for precise synergistic phototherapy and photoacoustic imaging of tumor apoptosis, Chemical Engineering Journal, 2021, 427: 130775.

  3.Jin Zhang; Mengqin Xu; Yongli Mu; Jinjie Li; Mohamed F. Foda; Weiyun Zhang; Kai Han; Heyou Han*; Reasonably retard O2 consumption through a photoactivity conversion nanocomposite for oxygenated photodynamic therapy. Biomaterials, 2019, 218, 119312.

  4.Jin Zhang; Yongli Mu; Zhaoyu Ma; Kai Han*; Heyou Han*; Tumor-triggered transformation of chimeric peptide for dual-stage-amplified magnetic resonance imaging and precise photodynamic therapy, Biomaterials, 2018, 182(182): 269-278.

  5.Mengqin Xu#; Jin Zhang#; Yongli Mu; Mohamed F. Foda; Heyou Han*. Activation of TRPV1 by An Acid-Responsive CaCO3 Nanocarrier for Tumor-Specific Therapy. Biomaterials, 2021, 121080.

  6.Huajuan Wang#; Jin Zhang#; Zhiyong Song#; Yongli Mu; MohamedF. Foda; Yang Wu; Heyou Han*; An intelligent platform based on acidity-triggered aggregation of gold nanoparticles for precise photothermal ablation of focal bacterial infection; Chemical Engineering Journal, 2021, 407: 127076.

  7.Yongli Mu#; Jin Zhang#; Mengqing Xu; Mohamed F. Foda; Yang Wu; Heyou Han*; Light-Induced Caspase-3-Responsive Chimeric Peptide for Effective PDT/Chemo Combination Therapy with Good Compatibility, ACS Applied Bio Materials, 2020, 3(4): 2392-2400.

  1.国家自然科学基金委员会, 青年科学基金项目, 51603080, 肿瘤细胞/亚细胞器双靶向多肽药物载体的设计及其在抑制肿瘤耐药性中的研究, 2017-01-01 至 2019-12-31, 20万元, 结题, 参与

  2.国家自然科学基金,重点研发计划,YF-ZLJCB2310-1-2,重组免疫细胞直接无损力学表征与诊疗产品质技控,2023-11-01至2028-10-01,52.7万,在研,参与

  3.国家自然科学基金委,重大研究计划,92159304,CAR-T体内命运及与胶质瘤酸性微环境时空相关性的可视化研究,2022-01-01至2025-12-31,350万,在研,参与